A laboratory study has linked lower levels of SIRT1 with a more active inflammatory signaling response in macrophages exposed to unusually high oxygen or LPS. Compared with normoxic controls, the stressed cells showed lower SIRT1 alongside higher TLR4 and NF-κB pathway activity, as well as more secreted IL-6, IL-1β and TNF-α. The finding identifies a pattern associated with oxidative or inflammatory stress; it does not by itself show that changing SIRT1 would prevent or treat bronchopulmonary dysplasia.
The work used RAW264.7 macrophages and MLE-12 alveolar epithelial cells, two cultured cell models used to examine the proposed relationship between macrophage signaling and alveolar epithelial cells. The reported baseline comparison centered on RAW264.7 cells. That distinction matters: the result is a response measured in a cell system, not a clinical outcome in infants.
The stress test
Researchers exposed the macrophages to 95% oxygen for 24 hours or to 1 μg/mL LPS for 24 hours. LPS was the inflammatory challenge in the comparison, while the high-oxygen condition modeled hyperoxia. Normoxic cells provided the reference point for judging changes in SIRT1 and inflammatory markers. Because both challenges were acute exposures in culture, the design captures a short-term cellular response rather than the full course of disease.
The central question was whether either challenge changed SIRT1 expression and inflammatory activation in macrophages. To measure SIRT1, the researchers used Western blotting, which detects protein levels, and quantitative reverse-transcription PCR, or qRT-PCR, which measures messenger RNA. They also assessed TLR4 and NF-κB-related readouts, including phosphorylated IκBα and p65, plus the inflammatory cytokines released into the culture medium.
The signal that emerged
In both hyperoxia and LPS conditions, SIRT1 was lower than in normoxic controls. At the same time, phosphorylated IκBα and p65, TLR4, and secreted IL-6, IL-1β and TNF-α were higher. In plain language, the two stress conditions tracked with a reduction in the protein the researchers were watching and a rise in several markers of inflammatory signaling. The analysis reports p-values below 0.001 or 0.01 for stated comparisons, but it does not provide the exact size of the molecular changes.
That pattern is consistent with the study’s proposed SIRT1-TLR4/NF-κB axis, in which SIRT1 is examined as a possible restraint on inflammatory signaling. But the evidence remains tied to the particular cell lines, exposure levels and assay readouts used here. A relative difference between stressed and normoxic cells cannot establish that SIRT1 loss caused the entire response, that TLR4/NF-κB is the only pathway involved, or that restoring SIRT1 would improve bronchopulmonary dysplasia.
A lead, not a treatment result
The presence of MLE-12 epithelial cells broadens the experimental system beyond macrophages, but the supplied result for the baseline comparison is specifically a RAW264.7 finding. The study therefore offers a mechanistic clue about how oxidative and inflammatory challenges may coincide with macrophage activation, not proof of an effect in a developing lung. That distinction is especially important when the experimental signals are reported without exact effect sizes or confidence intervals.
Further testing would need to determine whether the same SIRT1-TLR4/NF-κB relationship holds in more complete biological models and whether it changes epithelial outcomes in a reproducible way. For now, the result supports continued investigation of the pathway. It does not justify using SIRT1 modulation as a treatment for infants or treating the observed cell response as causal human evidence.
Paper data and sources
Original title: Targeting the SIRT1-TLR4 axis attenuates oxidative inflammation in a cellular model of bronchopulmonary dysplasia.
Authors: Wenhao Yuan, Lingxia Zhao, Guanguo Shen et al.
Journal/Repository: Pediatric research
Status: Peer-reviewed
First online: 2026-08-20
DOI: 10.1038/s41390-026-04812-z
Original paper · Full text